RadNet leadership emphasizes scale, diversity, and real-world relevance, portraying the program as delivering equitable results across racial, ethnic, and density groups.

Authors and affiliations indicate collaboration between DeepHealth and academic partners, with disclosures of corporate involvement and potential conflicts of interest.

Dr. Gregory Sorensen highlights the real-world, community-center setting and diverse population as strengths, noting AI improves access to specialist-level care.

RadNet media contact information is provided for further inquiries.

Looking ahead, the program plans continued outcome reporting and site-level performance summaries at RSNA 2025, with near-term metrics on site adoption and aggregated detection/recall data and longer-term signals on stage shift or survival benefits.

Data underpinning the findings are controlled by a supervising institutional review board and are not publicly accessible, as they are part of DeepHealth’s intellectual property.

The article underscores potential implications for broader access to specialist-level care and the benefits of early cancer detection regardless of location.

The ASSURE study, the largest real-world US analysis of AI-driven breast cancer screening, found RadNet and DeepHealth’s AI workflow increased cancer detection by 21.6% compared with state-of-the-art 3D mammography, raised positive predictive value by 15%, and kept recall rates within ACR guidelines, with benefits consistent across populations including over 150,000 Black women and a 22.7% boost for dense breasts.

EBCD™ is powered by DeepHealth’s Breast Suite, and the program has rolled out nationwide at RadNet-affiliated centers since 2023 to detect suspicious lesions earlier and improve treatment options.

The AI workflow combines an AI-based detection/diagnosis tool with a safeguard review where at-risk cases receive additional radiologist review to enhance early cancer detection.

The release includes forward-looking statements with cautionary language about potential risks and regulatory considerations that could affect realized benefits.

Standard forward-looking risk disclosures warn of regulatory, economic, and technological conditions that may influence outcomes.